A best evidence topic was written according to a structured protocol. The question addressed was what is the optimum prophylaxis against gastrointestinal haemorrhage for patients undergoing adult cardiac surgery: histamine receptor antagonists (H 2 RA) or protonpump inhibitors? A total of 201 papers were found; of which, 8 represented the best evidence. The authors, date, journal, study type, population, main outcome measures and results were tabulated. Only one randomized controlled trial (RCT) with relevant clinical outcomes was identified. The rest of the studies consisted of five prospective studies and two retrospective studies. In the RCT, there were no reported cases of gastrointestinal haemorrhage in the proton-pump inhibitor cohort, whereas 4 patients taking H 2 RA developed it. The rate of active gastrointestinal ulceration was higher in the H 2 RA cohort in comparison with the proton-pump inhibitor cohort (21.4 vs 4.3%). A prospective study followed 2285 consecutive patients undergoing cardiac surgery who received either no prophylaxis, or a proton-pump inhibitor. Chi-squared analysis showed the risk of bleeding to be lower in those receiving the proton-pump inhibitor (P < 0.05). Another study of 6316 patients undergoing coronary artery bypass grafting demonstrated a reduced risk of gastrointestinal bleed with prophylactic intravenous omeprazole (odds ratio = 0.2; confidence intervals = 0.1-0.8; P < 0.05). One study successfully showed that proton-pump inhibitors are effective in adequately suppressing gastric acid levels, regardless of Helicobacter pylori infection status; conversely, this study suggested that H 2 RAs were not. The evidence for H 2 RAs is marginal, with no study showing a clear benefit. One study showed that ulcer prophylaxis with H 2 RA did not correlate with the clinical outcome. Another study demonstrated gastric ulceration to be a common gastrointestinal complication in spite of regular H 2 RA use. There is also evidence to suggest that acid suppression increases the risk of nosocomial pneumonia, although open heart surgery may be a confounding factor in this association. Two RCTs showed that H 2 RAs may augment the immune system and reducing stress following cardiac surgery. Proton-pump inhibitors appear to be the superior agent for prophylaxis against gastrointestinal bleed in patients undergoing cardiac surgery, although rigorous comparative data are sparse. Furthermore, level-I evidence would confirm this.
INTRODUCTION
A best evidence topic (BET) was constructed according to a structured protocol as outlined in the best BETS document which is fully described in the ICVTS [1] . 
THREE-PART QUESTION

SCENARIO
You start at an adult cardiac surgery unit where intravenous (IV) ranitidine is used for prophylaxis against gastrointestinal (GI) haemorrhage (GIH). At your previous unit, omeprazole was used.
You wonder what the best agent is and resolve to search the literature yourself. 
SEARCH STRATEGY
DISCUSSION
A recent BET discussed whether routine stress ulcer prophylaxis is warranted [2] . Our BET seeks to answer which agent is superior. Fan et al. [3] followed up 6316 patients undergoing coronary artery bypass grafting (CABG) over 7 years and the frequency of GI complications. Univariate and multivariate analyses were conducted. Incidence of GIH was 0.33%. A total of 1327 patients within the cohort were given prophylactic IV omeprazole, which decreased the postoperative risk of GIH (P < 0.05) in comparison with patients who did not receive prophylaxis.
Gon et al. [4] compared how famotidine and rabeprazole affected perioperative gastric acid suppression, and the role of Helicobacter pylori infection in this. Thirty-three patients undergoing cardiac surgery were allocated to either agent. No GIH occurred in either group. Rabeprazole achieved sufficient acid suppression (average postoperative gastric pH >6) regardless of H. pylori status, unlike famotidine.
Hata et al. randomized patients to teprenone, ranitidine or rabeprazole, with GIH as a primary outcome [5] . There were no reported cases of GIH in the proton pump inhibitor cohort, whereas 4 patients developed bleeding complications in each of the other groups (P < 0.006). The incidence of haemorrhagic gastritis was also higher in these groups (teprenone = 22.9%; ranitidine = 15.7%) compared with the rabeprazole cohort (2.9%; P < 0.0003). Furthermore, active ulceration was significantly higher in these two cohorts compared with those taking PPI (P < 0.0001). Patients with ulceration were completely healed with 2 weeks of PPI therapy.
A prospective series conducted by Johnston et al. correlated risk factors with the incidence of GI complications post-cardiac surgery [6] . A total of 5438 patients were stratified according to their postoperative complications-no complications (Group I; n = 5369); acid peptic complications (Group II; n = 41) and other GI complications (Group III; n = 28). Patients with persistently low gastric pHs were started on H 2 RAs. Seventy-three complications were noted in 69 patients. Gastric ulceration was the most frequent complication despite routine use of H 2 RA. However, >15% of patients on prophylaxis in Group II received the medication for over 24 h.
A randomized controlled trial (RCT) assessed the effect of cimetidine on cellular immunity after cardiac surgery [7] . Twenty patients either received IV cimetidine pre-and postoperatively or were allocated to a control group. Natural killer cell activity was augmented and T-lymphocyte suppressor activity was decreased post-surgery in the test group. This suggests that cimetidine augments cellular immunity post-surgery, and may help prevent infection, e.g. from H. pylori.
Rosen's group [8] retrospectively matched 32 patients who developed postoperative life-threatening peptic ulcer complications (Group I) with 32 randomly selected patients (Group II) to compare risk factors and outcome. Perioperative IV cimetidine was administered to 15 patients in each group. Ten patients in each group had a history of previous peptic ulcer disease. In Group I, 11 mortalities occurred; of which, 7 were patients receiving prophylaxis. Group II incurred no mortality. The study deemed that ulcer prophylaxis did not correlate with the outcome. However, the average age of Group I was far greater than that of Group II. The authors also postulate that the degree of prophylaxis may have been inadequate.
Stchepinsky et al. [9] prospectively followed up 2285 consecutive patients; of whom 1151 received no GIH prophylaxis and 1134 received a PPI. Eight bleeding ulcers were noted in the former group, with 1 bleeding ulcer in the latter. There was no difference in the average age between the two populations. Chi-squared analysis showed a lower risk of bleeding in Group II (P < 0.05).
Tayama et al. [10] randomized 40 patients to cimetidine or a control cohort. Inflammatory markers were measured in all patients pre-and postoperatively. The treatment group yielded a postoperative decrease in IL-8, neutrophil elastase and C-reactive protein; and a concurrent increase in the lymphocyte recovery ratio. This suggests that cimetidine may help to reduce surgical stress and augment the immune system after cardiac surgery.
CLINICAL BOTTOM LINE
Prophylaxis against GIH in patients undergoing cardiac surgery has been part of routine perioperative practice for several decades [11] , but there are no guidelines regarding this. The data from the aforementioned RCT [5] indicate that PPIs are superior to H 2 RAs for GIH prevention following cardiac surgery; although H 2 RAs may have a role in enhancing immunity and diminishing postoperative stress [7, 10] . However, it is difficult to answer our central question-comparative, level-I evidence regarding the superior agent for this is sparse, with only two of the eight studies reviewed contrasting the two agents.
Acid suppression is not without its risks-it may be associated with an increased rate of nosocomial pneumonia in mechanically ventilated patients [12] [13] [14] , (although open heart surgery may be a confounding factor in this association). Several studies have indicated that PPIs may reduce the effectiveness of clopidogrel, a commonly prescribed agent for these patients [15] [16] [17] .
Conclusions drawn from the recent BET are similar to ours-the evidence is in favour of PPIs over other agents for GIH prophylaxis [2] . The quality and quantity of evidence are poor-only further comparative RCTs can confirm the superiority of PPIs.
